

Draft agenda
36th meeting of the Biocidal Products Committee (BPC)

6 - 8 October 2020

Meeting is held virtually via WebEx

**Starts on 6 October at 10:30,
ends on 8 October at 16:00**

The time is indicated in Helsinki time.

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-36-2020
For agreement

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-35

BPC-M-35-2020
For agreement

5. – Administrative issues

5.1. Administrative issues

For information

**5.2. Feedback received by SECR via questionnaire on virtual meeting
in June**

For information

6. – Work programme for BPC

**6.1. BPC Work Programmes for active substance approval, Union
authorisation, ED assessment and outlook for BPC**

BPC-36-2020-01; BPC-36-2020-02; BPC-36-2020-03; BPC-36-2020-04
For information

7. – Applications for approval of active substances*

7.1. Procedural and administrative aspects:

7.1.1. Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval

BPC-36-2020-05

For information

7.1.2. Working procedure for active substance approval

BPC-36-2020-06

For information

7.2. Article 75(1)(g) requests received:

7.2.1. Evaluation of the level of the risks for human health and for the environment of DBNPA used in biocidal products of product type 4

BPC-36-2020-07

For information

7.2.2. Evaluation of the level of the risks for human health and for the environment of cyanamide used in biocidal products of product types 3 and 18

BPC-36-2020-08

For information

7.2.3. Evaluation of the availability and suitability of alternatives to boric acid and disodium tetraborate pentahydrate for PT8

BPC-36-2020-09

For information

7.3. List of Endpoints for environmental exposure assessment for peracetic acid (PAA) and hydrogen peroxide

BPC-36-2020-10

For information and discussion

7.4. Draft BPC opinions on DDAC and ADBAC for PT 3 and 4

Previous discussion(s): WG-II-2020; BPC 28; WG-V-2017

DDAC PT 3: BPC-36-2020-11A, B, C

DDAC PT 4: BPC-36-2020-12A, B, C

ADBAC PT 3: BPC-36-2020-13A, B, C

ADBAC PT 4: BPC-36-2020-14A, B, C

For adoption

* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

7.5. Draft BPC opinion on the renewal of creosote for PT 8

Previous discussion: WG-I-2020

BPC-36-2020-15A, B, C
For discussion

7.6. Revised Assessment Report following the submission of data after active substance approval:

7.6.1. Active chlorine release from sodium hypochlorite for PT 1 - 5

BPC-36-2020-16
For agreement

7.6.2. Active chlorine release from calcium hypochlorite for PT 2 - 5

BPC-36-2020-16
For agreement

7.6.3. Active chlorine release from chlorine for PT 2 and 5

BPC-36-2020-16
For agreement

7.6.4. Copper pyrrithione for PT 21

BPC-36-2020-17, BPC-36-2020-18
For agreement

7.6.5. Salicylic acid for PT 2, 3 and 4

BPC-36-2020-19, BPC-36-2020-20, BPC-36-2020-21
For agreement

8. – Union authorisation**

8.1 Update on Union authorisation

For information

8.2 Working procedure for Union authorisation applications

BPC-36-2020-22
For agreement

8.3 Article 75(1)(g) request received on an Union authorisation application for a biocidal product family containing CMIT/MIT

BPC-36-2020-23
For information

** For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product family (denoted by D).

- 8.4 Consultation on an Union authorisation application for a biocidal product family containing CMIT/MIT**

For information

- 8.5 Draft BPC opinion on an Union authorisation application for a biocidal product containing clothianidin and pyriproxyfen**

Previous discussion: WG-II-2020

BPC-36-2020-24A, B, C, D

For adoption

9. - Any other business

- 9.1 Revision ECHA Guidance Volume III Human Health Information Requirements**

BPC-36-2020-25

For information

10. - Action points and conclusions

**Provisional time schedule for the
36th meeting of the Biocidal Products Committee (BPC)**

Virtual meeting via WebEx

6 October 2020: starts at 10:30; 8 October 2020 ends at 16:00

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

Tuesday 6 October: (starts at 10:30, ends at 17:00)

- | | |
|-----------|--|
| Items 1-5 | Opening items and administrative issues |
| Item 6.1 | BPC Work Programme for active substance approval, BPC Work Programme for Union authorisation, Outlook for BPC, Status ED assessment for active substances |
| Item 7.1 | Procedural and administrative aspects:
7.1.1. Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval
7.1.2. Working procedure for active substance approval |
| Item 7.2 | Article 75(1)(g) requests received:
7.2.1. Evaluation of the level of the risks for human health and for the environment of DBNPA used in biocidal products of product type 4
7.2.2. Evaluation of the level of the risks for human health and for the environment of cyanamide used in biocidal products of product types 3 and 18
7.2.3. Evaluation of the availability and suitability of alternatives to boric acid and disodium tetraborate pentahydrate for PT8 |
| Item 7.3 | List of Endpoints for environmental exposure assessment for peracetic acid (PAA) and hydrogen peroxide |
| Item 7.4 | Draft BPC opinions on DDAC and ADBAC for PT 3 and 4 |

Wednesday 7 October: (starts at 10:30, ends at 17:00)

- | | |
|----------|--|
| Item 7.5 | Draft BPC opinion on the renewal of creosote for PT 8 |
| Item 7.6 | Revised Assessment Report following the submission of data after active substance approval:
7.6.1. Active chlorine release from sodium hypochlorite for PT 1 - 5
7.6.2. Active chlorine release from calcium hypochlorite for PT 2 - 5
7.6.3. Active chlorine release from chlorine for PT 2 and 5
7.6.4. Copper pyrithione for PT 21
7.6.5. Salicylic acid for PT 2, 3 and 4 |

Thursday 8 October: (starts at 10:30, ends at 16:00)

- Item 8.1 Update on Union authorisation
- Item 8.2 Working procedure for Union authorisation applications
- Item 8.3 Article 75(1)(g) request received on an Union authorisation application for a biocidal product family containing CMIT/MIT
- Item 8.4 Consultation on an Union authorisation application for a biocidal product family containing CMIT/MIT
- Item 8.5 Draft BPC opinion on an Union authorisation application for a biocidal product containing clothianidin and pyriproxyfen
- Item 9 AOB
 - 9.1 Revision ECHA Guidance Volume III Human Health Information Requirements
- Item 10 Action points and conclusions

End of meeting

oOo